

**Maricopa Integrated Health Systems
Formulary Prior Auth Criteria**

Drug: Megace (Megestrol Acetate)

Therapy:

Is indicated for the treatment of advanced breast or endometrial (i.e. recurrent, inoperable, or metastatic) carcinoma

Is indicated for the treatment of HIV cachexia as an appetite stimulant for weight loss greater than 10% of baseline

Inclusions;

A) Breast and Endometrial Carcinoma

Request comes from an Oncologist

B) Females- Pregnancy tests prior or confirms that it is unnecessary

B) HIV Cachexia

- 1) Request comes from an HIV doctor
- 2) Height, initial weight and current weight
- 3) Failure of formulary alternatives
- 4) What nutritional supplements have been tried and failed

Black Box Warning:

Is a pregnancy category X drug, and may cause birth defects

Risk Factors/Contraindications:

Use with caution in patients with a history of thrombophlebitis

Patients with diabetes may need to adjust their insulin dose while on treatment.

Women who are pregnant or breast-feeding should not take this drug

Authorization:

Oncology-

Three months initially and continue authorization of one year with documented efficacy

HIV Cachexia-

Three months initially with continue authorization of six months with documented efficacy (weight gain)

Medical Director_____

Date_____